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Abstract
Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3
and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic
cells, especially when used in combination with cytarabine. This phase I study evaluated
nintedanib in combination with low-dose cytarabine (LDAC) in elderly patients with
untreated or relapsed/refractory acute myeloid leukemia (AML) ineligible for intensive che-
motherapy in a 3+3 design. Nintedanib (dose levels 100, 150, and 200 mg orally twice
daily) and LDAC (20 mg subcutaneous injection twice daily for 10 days) were administered
in 28-day cycles. Dose-limiting toxicity (DLT) was defined as non-hematological severe
adverse reaction CTC grade 4 with possible or definite relationship to nintedanib.
Between April 2012 and October 2013, 13 patients (median age 73 [range: 62–86] years)
were enrolled. One patient did not receive study medication and was replaced. Nine (69%)
patients had relapsed or refractory disease and 6 (46%) patients had unfavorable cytoge-
netics. The most frequently reported treatment-related adverse events (AE) were gastroin-
testinal events. Twelve SAEs irrespective of relatedness were reported. Two SUSARs
were observed, one fatal hypercalcemia and one fatal gastrointestinal infection. Two
patients (17%) with relapsed AML achieved a complete remission (one CR, one CRi) and
bone marrow blast reductions without fulfilling PR criteria were observed in 3 patients
(25%). One-year overall survival was 33%. Nintedanib combined with LDAC shows an
adequate safety profile and survival data are promising in a difficult-to-treat patient popula-
tion. Continuation of this trial with a phase II recommended dose of 2 x 200 mg nintedanib
in a randomized, placebo-controlled phase II study is planned. The trial is registered to
EudraCT as 2011-001086-41.
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Introduction
Acute myeloid leukemia (AML) is a clonal malignant disorder that results from genetic and
epigenetic changes in pluripotent stem or more differentiated progenitor cells [1]. It is predom-
inantly a disease of the elderly patient, with a median age at diagnosis of 70 years [2]. The clini-
cal course of AML is heterogeneous and response to therapy and outcome are influenced by
several patient- and disease-related features, including age, general performance status, comor-
bidities and cytogenetic aberrations [3, 4]. Older patients more frequently present with a com-
bination of unfavorable risk factors, including adverse cytogenetics and a higher frequency of
secondaryAML arising from antecedent hematological disorders, rendering their disease par-
ticularly difficult to treat. Of patients over 60 years of age only 25% survive two or more years,
even after intensive induction chemotherapy [5]. Consequently, there is an unmet need for
novel treatment strategies that provide efficacy and favorable tolerability for older patients
with AML who are unable to tolerate intensive chemotherapy regimens.
Nintedanib (BIBF 1120) is a potent, oral, small-molecule tyrosine kinase inhibitor of
VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β signaling [6], and has been recently approved
for second line treatment of non-small cell lung cancer (NSCLC) of adenocarcinoma histology
in combination with docetaxel. All three signaling pathways have been shown to play critical
roles in the regulation of angiogenesis, not only in solid tumors but also in hematological
malignancies such as AML [7]. Secreted by leukemic blasts, VEGF, bFGF and PDGF act in a
paracrine fashion on the bone marrow vasculature and stroma, which in turn promote leuke-
mia cell survival and growth [8, 9]. Interestingly, these ligand-receptor pairs are also involved
in autocrine signaling loops, in which leukemia-derivedgrowth factors directly support the
growth of VEGFR- [10–12], FGFR- [13–15], and PDGFR- [16] expressing leukemic cells. In
preclinical experiments, BIBF 1120 displayed potent growth inhibitory and proapoptotic
effects in various AML cell lines in the nanomolar range [17].
While the antibody-mediated pharmacological inhibition of single angiogenicmediators in
AML has been largely disappointing so far (e.g., bevacizumab) [18, 19], nintedanib offers the
theoretical advantage of simultaneously targeting multiple signaling pathways of pathophysio-
logical relevance, including both paracrine crosstalks betweenAML cells and vascular cells and
autocrine signaling loops in leukemic cells themselves. In addition, the compound exhibits
activity against the Src family members Src, Lyn and Lck as well as against Flt-3 [6], and thus
could represent a particularly attractive drug for AML therapy.
Here, we report the results of a phase I dose escalation trial of nintedanib combined with
low-dose cytarabine (LDAC) in elderly patients with untreated (de novo and secondary),
relapsed or refractoryAML not considered eligible for intensive chemotherapy.
Methods
Patients and eligibility
Elderly patients ( 60 years) with de novo, secondary, or previously treated AML (except acute
promyelocytic leukemia) according to the French-American-British (FAB) or World Health
Organization (WHO) classification not considered fit to receive intensive induction or salvage
chemotherapy were eligible for the study. Cytogenetics and NPM1, FLT3 and CEBPA muta-
tional status and assignment to risk groups according to the European LeukemiaNet (ELN)
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classification were done according to standard procedures. In patients with 20–30% bonemar-
row blasts, the indication for 5-azacitidine had to be considered prior to inclusion into the trial.
By amendment of March 2013, patients at risk for hollow organ perforation (i.e. patients with
ulcerative colitis, Crohn`s disease, or diverticulitis) could only be enrolled if the potential
benefit of the study participation outweighed the risk for perforation in the opinion of the
investigator. Exclusion criteria included: known central nervous systemmanifestation of AML;
inadequate liver function (ALT and AST 2.5 x ULN) unless caused by leukemic infiltration;
known chronically active hepatitis C infection or acute hepatitis; chronically impaired renal
function (creatinine clearance< 30 ml/min); uncontrolled hypertension with a resting systolic
blood pressure> 160 mmHg or diastolic blood pressure> 95 mmHg despite adequate treat-
ment; severe trauma or surgery within 4 weeks of study entry; severe, non-healing wounds,
ulcers or fractures; uncontrolled active infection; concurrent malignancies other than AML or
other severe diseases which in the opinion of the investigator were likely to influence the end-
point assessment; hypersensitivity to cytarabine (not including drug fever or exanthema); par-
allel participation in another clinical trial for the same indication; any severe concomitant
condition, which made it undesirable for the patient to participate in the study or which could
jeopardize compliance with the protocol. Written informed consent was obtained from all
patients before study enrolment.
Study design and treatment
The trial protocol, the CONSORT diagram and the TREND checklist are available as sup-
porting information (see S1 and S2 Protocols, S1 Fig and S1 Checklist). This was a prospec-
tive, single-center, dose escalation phase I study to assess the safety and tolerability of
nintedanib combined with LDAC in elderly patients with de novo or relapsed or refractory
AML unfit for intensive chemotherapy. The study was approved by the Ethics Committee of
the Physicians Chamber of Westfalia-Lippe and the University of Muenster, Germany, and
conducted in accordance with the Declaration of Helsinki and GoodClinical Practice. The
trial was registered to www.clinicaltrials.gov (identifier NCT01488344) and to EudraCT as
2011-001086-41.
Dose escalation was performed in a classical 3+3 design with 3 predefined dose levels of nin-
tedanib (100 mg twice daily for 28 days of a 28-day cycle in dose level (DL) 1, 150 mg in DL2,
and 200 mg in DL3) and patients were entered in cohorts of 3–6. Since a maximum tolerable
dose (MTD) for nintedanib in combination with various chemotherapeutic agents had already
been evaluated in clinical trials in solid tumors, an accelerated dose escalation to the recom-
mended dose of nintedanib in combination with chemotherapeutic agents (2 x 200 mg) was
chosen for the combination with LDAC. LDAC was administered from days 1–10 at 20 mg
twice daily by subcutaneous injection (Fig 1A). Toxicity was assessed by Common Terminol-
ogyCriteria for Adverse Events (CTCAE) version 4.0 criteria. Patients evaluable for safety anal-
ysis had to have received at least one dose of nintedanib and LDAC. The determination of the
MTD was based on the occurrence of dose limiting toxicities (DLTs) in the first treatment
cycle. In the absence of DLTs in the first cycle, dose escalation of nintedanib proceeded to the
next DL. In case of one DLT, up to 3 further patients were recruited into the same DL. The
highest DL with 1 DLT out of 6 patients was defined as the maximum tolerable dose (MTD)
and set as the phase II recommended dose (P2RD). In case a DL was considered for phase II
with less than 6 patients evaluated (i.e. no DLT in 3 patients), further patients were recruited to
reach a total of 6 evaluable patients. A DLT was defined as every severe adverse reaction CTC
grade IV with possible or definite relationship to nintedanib. Designated exceptions for DLT
determination included therapy-related cytopenias as signs of an intended anti-leukemic
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activity and cytopenia-associatedcomplications (neutropenic fever, neutropenic infections,
and thrombocytopenic bleedings).However, these complications could constitute a DLT if
occurring in an unexpectedhigh frequency, as judged by the DMC. Furthermore, complica-
tions such as neutropenic infections, thrombocytopenicbleedings, deterioration of the general
condition, laboratory abnormalities, death, tumor lysis syndrome, or organ failure, were also
excluded from DLT determination, whenever these were clearly attributable to AML progres-
sion in the judgment of the investigator. Adverse events (AE) of special interest (AESI) were
elevation of AST and/or ALT > 3x upper level of normal (ULN) combined with an elevation of
bilirubin> 2x ULN, and any hollow organ perforation occurring after the first intake of study
medication.
A bone marrow evaluation was done at the end of each cycle between days 24 and 28. Cycles
were scheduled every 4 weeks until progressive disease (PD), intolerance/toxicity, discontinua-
tion upon patient or investigator request, or achievement of a complete remission with or with-
out peripheral blood count recovery (CR or CRi) (Fig 1B). Patients with a partial remission
(PR) or stable disease (SD) continued treatment for up to 6 therapy cycles.
Fig 1. Study overview. (A) LDAC was administered at 20 mg twice daily subcutaneously on days 1 to 10 of a 28-day cycle. Nintedanib was taken
orally twice daily at three dose levels (100 mg, 150 mg, and 200 mg twice daily). Dose escalation was performed in a classical 3+3 design. (B)
Patients received up to 6 cycles of combination therapy until disease progression or achievement of a CR.
doi:10.1371/journal.pone.0164499.g001
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Endpoints
The primary objective was to evaluate the safety and tolerability of nintedanib combined with
LDAC to establish a P2RD. Secondaryobjectives were treatment response and overall survival
(OS).
Biomarker evaluation
Serum levels of VEGF and soluble VEGF receptor 2 (sVEGFR-2) were measured before treat-
ment initiation and after each therapy cycle by enzyme-linked immunosorbent assays accord-
ing to the manufacturer`s instructions (R&D Systems, Minneapolis, USA).
Statistical analysis
Baseline disease characteristics and demographic data of all patients were summarized descrip-
tively, using medians, means and ranges. All patients who received at least one dose of ninteda-
nib and LDAC were included into the analysis of safety, tolerability and efficacy. OS was
measured from the first day of treatment until death of any cause and was estimated using the
Kaplan-Meier method. Correlations between serum angiogenicmediators were assessed using
the Pearson correlation coefficient.The Wilcoxon matched-pair signed rank test was used to
compare levels of angiogenic factors in individual patients at diagnosis and following study
treatment. Two-sided P values lower than 0.05 were considered to indicate significant differ-
ences. All analyses were performed using the SPSS Statistics software package, version 22.0
(IBMCorp., Armonk, NY, USA).
Results
Patients
BetweenApril 2012 and October 2013, 13 patients with a median (range) age of 73 (62–86)
years were enrolled (DL1 (n = 3), DL2 (n = 4), DL3 (n = 6)). One patient in DL2 did not receive
study medication due to rapid AML progression and deterioration of general condition and
was replaced. Table 1 summarizes the clinicopathological characteristics of all patients. The
majority of patients (n = 9, 69%) had relapsed (n = 5) or refractory (n = 4) AML and had
received one or more prior therapies (median (range) 2 (0–3)), including intensive chemother-
apy regimens (n = 9), allogeneic hematopoietic stem cell transplantation (n = 1), 5-azacitidine
(n = 1), and experimental compounds (n = 3). Four patients (31%) were enrolled with newly
diagnosedAML (two with de novo and two with secondaryAML). Median ECOGperfor-
mance status (range) was 1 (1–3). According to ELN criteria, six patients (46%) had adverse
risk, five (38%) had intermediate risk, and one patient (8%) had favorable cytogenetic / molec-
ular risk (unknown in one patient). An internal tandem duplication in the fms-like tyrosine
kinase 3 gene (FLT3-ITD) was found in one patient.
Safety and tolerability
Four patients (33%) received one course of treatment, five (42%) received two, two (17%)
received three, and one (8%) received six cycles. In total, five tablets of nintedanib were not
taken in three patients, corresponding to a compliance rate of 99.6%. No DLTs were reported
during dose escalation to DL3. Thus, three additional patients were enrolled at DL3 and 200
mg nintedanib twice daily was designated as the P2RD in combination with LDAC since no
DLTs occurred in a total of six patients treated at DL3.
Overall, the safety profile of nintedanib was similar to that reported in previous studies [20].
The most common AEs of any grade associated with nintedanib treatment as determined by
Nintedanib and LDAC in AML
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the investigators were gastrointestinal AEs, including diarrhea (n = 9), nausea (n = 7) and eme-
sis (n = 6) (Table 2). Nintedanib-related grade 3 AEs were reported in four patients. Irrespec-
tive of relatedness, 17 grade 3 AEs were reported in 9 patients. The most common of which
were febrile neutropenia and gastrointestinal disorders, which each occurred in two patients. A
complete list of all AEs can be found in S1 and S2 Tables.
A total of 12 SAEs (codedwith 17 MedDRA codes) were reported in nine patients, one at
DL1, four at DL2, and seven at DL3. All were single events except neutropenic fever, which was
reported 4 times in three patients and pyrexia, which occurred in two patients (Table 3). SAEs
had to be reported until 28 days after last protocol treatment. Death due to acute myeloid leu-
kemia progression was reported as SAE in one patient. One additional patient died from dis-
ease progression before start of therapy but after signing informed consent. No AESIs were
observed in this study. Two suspected unexpected severe adverse reactions (SUSARs) were
reported in two patients at DL2 and DL3, respectively. One patient developed a fatal gastroin-
testinal infection, and no fatality has been previously reported for gastrointestinal infection
caused by nintedanib. The other patient experiencedhypercalcemia due to unknown reasons
in a phase of AML progression and died shortly after. Serum alkaline phosphatase and
Table 1. Patient demographics and baseline disease characteristics.
n = 13
Median (range) age, years 73 (62–86)
Male/female, n 7/6
ECOG performance status, n
0 0
1 9
2 2
3 2
Disease status, n
untreated 4
de novo 2
secondary 2
relapsed 5
refractory 4
FAB classification, n
M0/M1/M2 6
M4/M5 5
M6 1
unclassified 1
ELN risk, n
favorable 1
intermediate 5
adverse 6
missing 1
Median (range) WBC count, x 109/L 2.71 (0.90–77.40)
Median (range) peripheral blasts, % 9 (0–87)
Median (range) of bone marrow infiltration, % 60 (20–80)
Median (range) previous lines of therapy, n 2 (0–3)
FAB: French-American-British classification for AML; ELN: European Leukemia Net; WBC: White blood
cells
doi:10.1371/journal.pone.0164499.t001
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Table 3. SAEs, SARs, SUSARs and AESIs reported in the study (presented by relatedness to ninteda-
nib, MedDRA codes for overall 12 cases, MedDRA v15.1).
MedDRA preferred term n Max. CTCAE grade Dose level
SAE 11
Febrile neutropenia 4 3 DL2, DL3
Pyrexia 2 2 DL1, DL3
Thrombocytopenia 1 4 DL2
Atrial flutter 1 3 DL3
Renal failure acute 1 3 DL3
Pneumonia 1 2 DL3
Acute myeloid leukemiaa 1 5 DL3
SAR 4
Diarrhoea 1 3 DL3
Vomiting 1 2 DL3
Nausea 1 2 DL3
Abdominal pain upper 1 2 DL3
SUSAR 2
Hypercalcaemia 1 5 DL2
Gastrointestinal infection 1 5 DL3
AESI 0
- - - -
aThis patient experienced lethal “Acute myeloid leukemia progression”, coded with MedDRA preferred term
“Acute myeloid leukemia”
doi:10.1371/journal.pone.0164499.t003
Table 2. Frequency of patients with nintedanib-related adverse events across all dose levels.
MedDRA preferred term (v15.1) All gradesa, n Grade 3, n
Diarrhoea 9 1
Nausea 7 0
Vomiting 6 0
Constipation 3 0
Blood bilirubin increased 2 0
Dry mouth 2 0
Hypotonia 2 0
Pyrexia 2 0
Gastrointestinal infection 1 1
Hypercalcaemia 1 1
Hyperuricaemia 1 1
Abdominal distension 1 0
Abdominal pain 1 0
Abdominal pain upper 1 0
Asthenia 1 0
Alkaline phosphatase increased 1 0
Decreased appetite 1 0
Dysgeusia 1 0
Eructation 1 0
Headache 1 0
aNote: Data represent the highest CTCAE grade reported.
doi:10.1371/journal.pone.0164499.t002
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parathyreoid hormone were within the normal range in this patient, but further evaluation of
hypercalcemia was not possible since the patient requested transferral to a hospice. Hypercalce-
mia had not been associated with nintedanib so far.
Treatment outcome
Two out of 12 treated patients (17%) had an objective response to nintedanib combined with
LDAC. A CR lasting one month was reported in one patient after three courses at DL1, with an
additional patient achieving a CRi of four months after the first cycle at DL2. Both patients had
relapsed disease after intensive chemotherapy when enrolled in the study. SD was reported in
five patients, with three of them showing significant reduction of bone marrow blasts, and four
patients experiencedPD. The patient with fatal GI tract infection died before response evalua-
tion (indeterminate cause). All patients responding with a CR/CRi or a blast reduction were
FLT3-ITD negative.
All patients had died at the time of OS evaluation.Median OS of the treated study cohort
was 234 days and 1-year survival was 33.3% (95% confidence interval (CI), 10.3–58.8%) (Fig
2). Interestingly, one patient who had persisting leukemia after two courses of nintedanib and
LDAC at DL3 survived almost two years after start of therapy with best supportive care but
without further specific anti-leukemic treatment.
Serum levels of angiogenic mediators during treatment with nintedanib
and LDAC
Mean serum levels (range) of VEGF and sVEGFR-2 obtained from 8 patients at baseline were
117 pg/mL (40–831 pg/mL) and 1500 pg/mL (696–1817 pg/mL), respectively. VEGF levels
positively correlated with sVEGFR-2 levels (r = 0.419, P = 0.042). In patients in whom post-
therapeutic blood samples were available, sVEGFR-2 concentrations significantly decreased
after the first cycle of therapy as compared to baseline (median 1500 vs. 1169.5 pg/mL,
P = 0.046,Wilcoxon test), while VEGF did not significantly differ (67.5 vs. 163.5 pg/mL,
P = 0.173) (Fig 3). However, there was no apparent relation between therapy-induced changes
in VEGF or sVEGFR-2 levels and response to therapy.
Discussion
This single-arm dose escalation trial was the first to investigate the safety and efficacy of the tri-
ple angiokinase inhibitor nintedanib added to standard LDAC therapy (400 mg over ten days)
in elderly patients with newly diagnosed, relapsed or refractoryAML. Using a classical 3+3
design no DLTs were reported and no safety concerns emerged from combination treatment.
The dose level of 200 mg taken twice daily was established as the recommended phase II dose.
In fact, 200 mg twice daily is the dose at which nintedanib has recently been approved for the
treatment of advanced NSCLC in combination with docetaxel [20].
Overall, the toxicity profile of nintedanib observed in this study is consistent with previous
large phase III studies of nintedanib as single-agent [21] or in combination with chemotherapy
[20]. The only unexpected adverse reaction was a fatal hypercalcemia, besides a fatal outcome
of an otherwise expected gastrointestinal infection. Since this hypercalcemia occurred in a
patient with progressive disease, an association with disease progression within bone marrow
is possible. As expected, gastrointestinal toxicities were the main nintedanib-related AEs
reported. In fact, the orthogonal spectrumof side effects, with myelosuppression being the
most relevant toxicity for LDAC [22] and with gastrointestinal adverse effects for nintedanib,
should facilitate combinability between these two agents.
Nintedanib and LDAC in AML
PLOS ONE | DOI:10.1371/journal.pone.0164499 October 7, 2016 8 / 13
Elderly patients with newly diagnosedAML can expect a 13–19% chance of remission from
treatment with single-agent LDAC [22–24], while there are no data available on the efficacy of
LDAC monotherapy beyond first-line. In the study reported here, a CR rate of 17% has been
observed in a cohort in which two-thirds of patients had relapsed or refractoryAML and in
which half of patients had unfavorable cytogenetics, thus representing a particularly difficult-
to-treat elderly population. Interestingly, these two CRs were achieved in patients who were
enrolled in the study with relapsed AML after intensive cytarabine-based induction chemo-
therapy. Furthermore, the 1-year OS rate of 33% observed in our cohort with the combination
of LDAC and nintedanib is a promising preliminary finding, although caution has to be taken
given the small cohort and the wide confidence interval. Given that the majority of patients
entered the study in a relapsed or refractory situation, this would compare favorably with
1-year OS rates for single-agent LDAC in chemotherapy naïve patients of 22–25% [22–24],
even though the most recent United KingdomMedical Research Council (MRC) non-intensive
AML studies in treatment-naïve patients indicate similar 1-year OS rates of approximately
Fig 2. Kaplan-Meier curve of overall survival. Median OS of treated patients was 234 days, and one-year OS (95%
CI) was 33.3% (10.3–58.8%).
doi:10.1371/journal.pone.0164499.g002
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30% with LDAC [25]. The reasons for the encouragingOS in the absence of a higher CR rate
and a prolonged remission duration in our study are not obvious. Similar findings, however,
have beenmade with demethylating agents, which are able to provide a survival advantage in
elderly patients with AML not responding with a CR [26–28]. Interestingly, one patient treated
with LDAC and nintedanib at the highest dose level survived almost two years after treatment
initiation with persisting leukemia and best supportive care, but without further specific anti-
leukemic therapy.
Bone marrow and circulating levels of VEGF and its receptors have been consistently
shown to be increased in AML patients as compared to healthy individuals [10, 29, 30], indicat-
ing that the VEGF/VEGFR axis plays an important role in the pathophysiology of the disease
[11, 12]. In the present study, treatment with nintedanib and LDAC was associated with a
decrease of sVEGFR-2 serum concentrations, whereas blood levels of VEGF did not change
significantly. Although the mechanisms responsible for the decrease of circulating VEGF
receptors upon small molecule inhibition are not fully understood, our results are entirely in
line with previous observationsmade with nintedanib in solid tumors [31] and with other
kinase inhibitors targeting VEGFR-2 such as cediranib [32] or AG-01736 [33] in AML. Alter-
natively, the observeddecrease in sVEGFR-2 levels could also be attributed to the acute reduc-
tion of the leukemic burden by LDAC. Thus, it remains to be seen whether sVEGFR-2 might
serve as a valuable pharmacodynamic indicator of nintedanib drug exposure when used in
combination with chemotherapy in AML.
In conclusion, adding nintedanib to LDAC at a RP2D of 200 mg twice daily was found to be
safe in elderly patients with AML. Based on the encouraging survival data obtained in phase I,
a randomized, placebo-controlled,multi-center phase II study evaluating the efficacy of the
combination of nintedanib and LDAC is in preparation.
Fig 3. Changes in VEGF and sVEGFR-2 serum concentrations during therapy. While pre- and post-therapeutic levels of VEGF did not
significantly differ (median 67.5 vs. 163.5 pg/mL, P = 0.173, Wilcoxon test), sVEFGR-2 serum concentrations significantly decreased after one
cycle of study therapy (1500 vs. 1169.5 pg/mL, * P = 0.046).
doi:10.1371/journal.pone.0164499.g003
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